ERBA Diagnostics Mannheim acquires Lumora

Cambridgeshire, UK, 7 September 2015... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, has been acquired by ERBA Diagnostics Mannheim, a leading global player in the in-vitro diagnostics market.

The acquisition will see Lumora’s molecular diagnostics

Lumora Sells Heat Elution Technology to Roche

Cambridgeshire, UK, 24 August 2015... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical research and industrial markets, has sold its proprietary nucleic acid Heat Elution purification technology¹ to Roche.

Roche has signed a definitive Asset Purchase Agreement with

Lumora Named as ‘Company to Watch in 2015’ by Leading Industry Publisher

Cambridgeshire, UK, 24 March 2015... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, has been named as a company to watch in 2015 by Kalorama, a leading publisher of market research in medical markets.

The report, ‘The

Lumora’s patented Sample Preparation technologies in Commercial Use 

Cambridgeshire, UK, 16 March 2015... Lumora, a provider of state-of-the-art

Lumora Extends Heat Elution sample prep application

Cambridgeshire, UK, 11^th November 2014... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, today announces it has completed testing of its latest application of its Heat Elution molecular sample preparation technology, for food pathogen sample

Lumora Secures New India Patent for its BART portfolio Technologies

Cambridgeshire, UK, 30 September 2014... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has secured a further patent for its growing portfolio of BART-related (Bioluminescent Assay in Real Time) technologies with the granting of its

Lumora Technology Used in Latest BioGal Diagnostic

Cambridgeshire, UK, 4 September 2014... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has expanded its commercial partnership with Biogal Galed Labs, a global leader of veterinary diagnostic solutions. 

The expanded partnership will see

For immediate release

Lumora Develops New Rapid DNA Extraction Kit

Cambridgeshire, UK, 27 July 2014... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, announces the completion of the development of its Buccal Swab DNA Extraction Kit at the AACC conference in

For immediate release

Lumora Develops RapidMag, a New Sample Preparation Tool

Cambridgeshire, UK, 17 May 2014... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has developed RapidMag, a new sample preparation tool for whole blood and

For immediate release
New England Biolabs® announces supply agreement with Lumora.
Agreement further strengthens New England Biolabs' position as a key supplier to the molecular diagnostics sector.

5th March, 2014 (Ipswich, MA, USA) New England Biolabs, Inc. (NEB®), a world leader in the production and supply of recombinant enzymes and related reagents for

UNITAID Report Highlights Lumora’s Technology for Viral Load Monitoring for HIV

Cambridgeshire, UK, 17 February 2014

Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has been named in the UNITAID HIV/AIDS Diagnostic Technology Report that highlights innovative new diagnostic technologies for viral load monitoring

Hayden Jeffreys Appointed to Board of Lumora

Cambridgeshire, UK, 22 January 2014...

Lumora, a successful provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, is pleased to announce that it has appointed Hayden Jeffreys to its Board of Directors.

Hayden joined Lumora from Lab21 in January 2013 as

Under embargo for
17:00 EST/22:00 GMT 8 January 2014

New technology applied to rapidly detect C. difficile in a clinical setting 
PLOS research shows new technique is more than twice as fast as current gold standard

Cambridgeshire, UK, 8 January 2014...

Lumora, a provider of state-of-the-art molecular diagnostic products

Lumora completes follow on fundraising

Company raises £700,000 to accelerate commercial development

Cambridge, UK, 18th March 2013... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has completed a follow on fund raising as it looks to

Lumora appoints Industry Veteran, Jim Reid, as Chairman as Company gears up for major commercial push

Cambridge, UK, Monday 11 February 2013...Lumora, a provider of state-of-the-art molecular diagnostic products into both the clinical and industrial markets, has appointed Jim Reid as Chairman.

Jim brings a wealth of experience

Lumora shortlisted in Best Novel Agricultural Biotechnology category of AGROW awards 2012. Winners to be announced at the awards ceremony on 7th November 2012 in London. Click here for further information.

Lumora article "Developing a bioluminescent assay for viral load monitoring in HIV" featured in May 2012 edition of IVD Technology

14th May 2012

The May edition of IVD Technology has just been published and carries the article "Developing a bioluminescent assay for viral load monitoring in HIV". It describes how the new technology could address the significant and so

Lumora welcomes expressions of interest for GMO test commercialisation after BART technology demonstrates ability to detect genetically modified contamination of crops rapidly and at very low levels on a portable instrument

30th April 2012

Lumora announces Joint Development and Licensing Agreement with 3M for its innovative BART technology.

31 August 2011

Lumora to present at two international conferences in September 2011

31 August 2011: London, UK: Lumora Ltd, Headquartered in Ely, Cambridgeshire, and 3M headquartered in St Paul, Minnesota, USA have signed a

Lumora Attracts Series B Funding.

26 May 2011

Lumora Ltd, the Molecular diagnostics company, developing next generation tests through its proprietary BART Technology platform, has secured £1.5 million from the completion of the company’s latest funding round, led by Catapult Venture Managers Ltd.

The capital injection will primarily be used to

BART technology published in respected scientific journal.

07 December 2010

Lumora is delighted to announce publication of a peer reviewed article in the Public Library of Science. The article describes Lumora's core BART technology detailing both the underlying biochemistry of the BART technology as well as its unique practical applications to molecular

Lumora recognised as one of the leading HealthTech companies in the UK.

07 December 2010

Lumora have been selected to represent the UK on a technology mission to San Francisco in January 2011 aligned with the JP Morgan Healthcare Conference where we will explore opportunities for growth with key investors, potential partners and customers, media and other

Lumora Secures TSB funding for Point-of-Care Clinical Sample Preparation.

11 August 2010

Lumora attracts funding of over £100,000 from the Technology Strategy Board (TSB) to support the company’s development of a rapid sample preparation solution for molecular diagnostics at the point of care. The funds will be used to develop a universal, single step,

Lumora is attending the AACC Conference on 25-28th July.

15 July 2010

Laurence Tisi (CEO) and Paul Weinberger (CMO) will be attending the annual AACC conference in Anaheim between the 25th and 28th of

Paul Weinberger joins Lumora.

17 May 2010

Lumora is pleased to announce today the appointment of Paul Weinberger as Chief Marketing Officer. Paul will be responsible for Corporate Marketing and Business Development, including licensing and commercial agreements. He brings extensive experience of molecular diagnostics business development from both

Lumora is attending the 40th MEDICA conference in Düsseldorf.

18 November 2009

Lumora will be attending the 40^th annual meeting at MEDICA in Düsseldorf on the 18-20^th November 2009.

Laurence Tisi PhD, CEO will be representing Lumora, where he will meet with potential partners interested in commercialising the molecular

Lumora makes the inaugural Killer Technology List.

22 September 2009

Lumora has been listed in the inaugural Business Weekly "Killer Technologies" league table of the 50 most disruptive technology businesses in the East of England.

...

Lumora speaking at the XIII International Symposium on Luminescence Spectroscopy.

02 September 2009

Lumora will be presenting two talks at the XIII International Symposium on Luminescence Spectroscopy, September 7-11, 2008 in Bologna, Italy:

1. Simpler hardware using brighter assays: BART technology
   (Sept. 10th, Session H2,

Lumora is attending the CoExtra International Conference in Paris.

03 June 2009

Lumora will be attending the CoExtra International Conference in Paris on 3-5 June 2009, and will be presenting talks and technology demonstrations:

1. June 3rd, Session B2, 16:40: ‘Non-PCR based alternative analytical methods.’ (Guy Kiddle).
2. June 4th: